Publications by authors named "Andrew Boon Ming Lim"
G-CSF only mobilisation has been shown to enhance immune reconstitution early post-transplant, but its impact on survival remains uncertain. We undertook a retrospective review of 12 transplant centres to examine overall survival (OS) and time to next treatment (TTNT) following melphalan autograft according to mobilisation method (G-CSF only vs. G-CSF and cyclophosphamide [CY]) in myeloma patients uniformly treated with bortezomib, cyclophosphamide and dexamethasone induction.
View Article and Find Full Text PDFArticle Synopsis
- The KEYNOTE-185 trial studied the addition of pembrolizumab to the standard treatment of lenalidomide and dexamethasone in newly diagnosed, transplant-ineligible multiple myeloma patients to evaluate potential increases in treatment efficacy.
- This phase 3 trial involved 301 participants from 15 countries, and randomly assigned them to receive either the combination of the three drugs or just lenalidomide and dexamethasone.
- An unplanned interim analysis was conducted to assess the combination's safety and effectiveness, particularly focusing on progression-free survival due to early termination of the trial as requested by the FDA.